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Changes in Clinical Diagnostics and 
Tracking Infectious Diseases
2The Impact of Culture-independent Diagnostic Testing 
in Foodborne Diseases
Christopher Braden, MD
Deputy Director
National Center for Emerging and Zoonotic Infectious Diseases
3Diagnostic Methods Through Time
1860s: 
Culture-based tests 
Invented by French 
scientist Louis Pasteur, 
a.k.a., the “father 
of microbiology”
1980s-90s: 
Antigen-based tests
Detect antigens  
specific to 
pathogen type 
2000s: 
Polymerase Chain 
Reaction (PCR) tests
Detect short genetic 
sequences specific 
to pathogen type
2010s: 
Multiplex PCR panels
Use PCR to detect one or 
multiple pathogens 
simultaneously, often 
designed for disease 
syndromes, can detect 
viral pathogens
Culture-independent Diagnostic Tests
4Number and Types of Culture-independent Diagnostic 
Tests Are Increasing
STEC: Shiga toxin-producing E. coli 
Names of products are provided for identification purposes only and do not imply any endorsement by the CDC
Antigen-based tests 
(FDA cleared)
•3 tests for Campylobacter
•2 tests for STEC
Antigen-based tests 
(FDA cleared)
•3 tests for Campylobacter
•5 tests for STEC
Laboratory-developed tests
(not FDA cleared)
•Molecular detection (PCR) 
tests for single or multiple 
pathogens
Multiplex PCR panels 
(FDA cleared)
•Luminex
•Nanosphere
•ProGastro SSCS
•BD Max
•BioFire
2011
2016
5Use of Culture-independent Diagnostic Tests (CIDT) Is Increasing
 For diagnosing enteric infections, 
increases in CIDT use show
● Uptake varies by pathogen
● Growing use of multiplex PCR panels
 For surveillance and tracking, 
increases in CIDT impacts trends 
● Increased incidence of Cryptosporidium and 
non-O157 Shiga toxin-producing E. coli (STEC) 
might be due to increased use of CIDTs
April 2016 FoodNet MMWR
2015 – updated since April 2016 MMWR to include most current data, not yet published 
Bacterial infections diagnosed by culture-
independent diagnostic tests without 
culture confirmation, 2012–2015
P
e
rc
e
n
t 
o
f 
b
ac
te
ri
al
 in
fe
ct
io
n
s
6
7 8
16
0
2
4
6
8
10
12
14
16
18
2012 2013 2014 2015
Year
6Multiplex PCR Panels – Generic Workflow
SPECIMEN
SAMPLE TUBE
WITH REAGENTS
INSTRUMENT POSITIVE
NEGATIVE
t=0 t=5 min t=1–2hr t=24–72hr
REPORT
Multiplex PCR and
Target Detection
RESULTS 
Reflex 
Culture
REFLEX CULTURE
A REFLEX CULTURE is a 
test done when initial 
testing is positive 
and additional 
information is needed.
7The Benefits of Using CIDT for Diagnosis
Faster results
Targeted treatment
Single test can detect or rule out 
multiple pathogens (e.g., viruses, 
parasites, and bacteria)
Likely more sensitive than culture
Faster information for local public 
health action 
8CIDT Do Not Provide Isolates Nor Characterize Pathogens
CIDT do not provide isolates
Reflex cultures needed to characterize 
the pathogen
● Antimicrobial susceptibility
 Tailor treatment
 Track resistance trends
● Virulence factors
● Serotype
● Genotype (i.e., DNA fingerprints) 
 Identify outbreaks
9Why is Pathogen Characterization Important 
for Food Safety?
PulseNet connects cases 
to identify outbreaks
Detailed DNA fingerprints 
facilitate outbreak detection
● DNA analyses with whole genome 
sequencing technology 
require cultured isolates
Each year, 48 million people get 
sick, 128,000 are hospitalized 
and 3,000 die from foodborne diseases
www.cdc.gov/pulsenet
National Outbreak Reporting System
Public Health Uses Pathogen Characterization to Detect and Stop Foodborne Outbreaks
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Other Drawbacks of CIDT: 
Positive Results Can Be Difficult to Interpret
Buss SN, Leber A, Chapin K, et al. 2015. Multicenter evaluation of the BioFire FilmArray Gastrointestinal Panel for etiologic diagnosis of infectious 
gastroenteritis. J Clin Microbiol 53:915–925
DNA from dead microbes can produce a positive result
● Clinicians may not know if patient is still contagious
● Unclear if it’s safe for patient to return to work or day care
A single test may detect multiple pathogens, some of which may not 
be causing illness 
● One study found that over 30% of positive tests detected more than one enteric 
pathogen
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Strategies to Meet the Surveillance Challenge of CIDT
Requirement
1. Use of reflex 
culture to 
obtain isolates
Requirements
1. Continued use of 
reflex culture 
2. Development of large 
genome database
Requirements
1. Identify subtyping 
targets for amplicon 
sequencing
2. Refine shotgun 
metagenomics methods
Whole Genome Sequencing Culture-based Metagenomics
Short-term Current Long-term
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Building a Broad Set of Partnerships
ADX: AdvaMedDx CLIA:  Clinical Laboratory Improvement Amendments 
APHL: Association of Public Health Laboratories CSTE:  Council of State and Territorial Epidemiologists
ASM: American Society for Microbiology IDSA: Infectious Diseases Society of America
Maintain access to cultures in 
short term and work toward the 
future of CIDTs
● Building the coalition
● Raising awareness
● Publishing information
● Tracking progress
● Adapting surveillance methods
Partnership
States
CLIA
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Managing New Diagnostic Tests in Colorado
Alicia Cronquist, RN, MPH
Foodborne Disease Program Manager
Communicable Disease Branch
Colorado Department of Public Health and Environment
14
Impact of CIDT on Surveillance and Isolate Recovery in Colorado
STEC:  Shiga toxin-producing E. coli
Unpublished data, Colorado Department of Public Health and Environment
Since 2013, 15 labs use CIDT (e.g., multiplex PCR testing) 
● So far in 2016, 40% of bacterial enteric cases reported were tested using PCR (N=537)
 For Campylobacter, Salmonella, Shigella, STEC, Vibrio, Yersinia
● Reflex culture performed for 89% of the Salmonella, Shigella and STEC tested with PCR 
Impact on surveillance in Colorado
● Ensure accurate case reporting
● Facilitate isolate recovery
● Adapt public health practice to new type of ‘cases’ being reported
 Previously only culture-confirmed reports were considered ‘cases’ 
 ‘Probable case’ definitions include CIDT-positive results
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Accurate Case Reporting:  Understanding Which Tests 
Are Used and By Whom
Routine survey of
laboratory methods
● Established in 2009
● Twice per year in FoodNet 
catchment area (Denver 
metropolitan area)
● Once per year in rest of state
● Labor intensive
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Accurate Case Reporting: Collecting the Right Information
Modify disease surveillance database to capture data from new tests
● Collaborate with IT department 
Ensure correct reporting of CIDT results
● Change settings so electronic laboratory reporting (ELR) data flow correctly
● Correct test names in printed case reports sent to public health
 Reporting “culture” for Salmonella when results were from CIDT
● Address human error in interpreting multiplex panel results
 Disease and test names sound alike and can be confusing
e.g., Shigella, Shiga toxin-producing E. coli (STEC), Plesiomonas shigelloides
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Accurate Case Reporting: Outreach Is Important
Education and communication are key
Create guidance documents 
Hold frequent meetings with 
stakeholders
● Infection preventionists
(e.g., hospital epidemiologists)
● Laboratories
● Local public health partners
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Isolate Recovery at Clinical Laboratory Is Preferred 
Where is reflex culture performed?
● Hybrid approach in Colorado
Isolation at clinical laboratory is preferred
● Faster results
● Less concern about transit of raw specimens
● Susceptibility results available for patient care 
Outreach to clinical laboratories that 
adopt CIDT
● Request reflex cultures for Salmonella, Shigella
and Vibrio
● Review isolate submission protocols
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Isolate Recovery at the State Public Health Laboratory (SPHL) 
Clinical material sent from laboratory to SPHL
● Isolate recovery done at SPHL
Determine resources 
● Select priority pathogens: STEC, Salmonella, Shigella, Vibrio
● Seek additional funding for culture
Review and modify Board of Health reporting 
regulations and submission requirements 
● “Isolates or clinical material” of selected pathogens
● Required, no longer voluntary
STEC: Shiga toxin-producing E. coli
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Facilitating Specimen Submissions to the State Public 
Health Laboratory (SPHL) 
Facilitate rapid delivery to SPHL
● Courier service to ensure regular service where needed
Provide transport media
Written guidance based on new APHL studies
Continuous improvement and education
● Work with laboratories when specimen sent incorrectly
APHL: Association of Public Health Laboratories
21
Adapting Public Health Practice
Increase in case reports with less certainty about each one
Some data received more quickly, but lag time increased for others
● Subtyping data is delayed
Implement new case definitions
● Collect more detailed test data
● Capture pertinent negative results (e.g., PCR positive but culture negative)
Train staff to appropriately assign case status
● Create new algorithms and guidance documents
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Adapting Public Health Practice:  Case Investigation
Establish and evaluate guidance 
Prioritize which cases should 
be investigated
● Consider local resources
● Priority based on disease and test results   
Timing of case investigation 
● If public health will investigate, 
don’t wait for culture results 
● Other jurisdictions might make different decisions  
www.colorado.gov/cdphe
Consider Photo here
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Adapting Public Health Practice: Exclusions and Treatment  
Worker and childcare exclusion or restriction for 
PCR-positive results
● Treating PCR-positive results like culture
● Follow up testing is often done at SPHL at no charge 
Handling patients CIDT positive for 2 or more 
reportable conditions 
● Treatment and disease control decisions
● Choose control measures for pathogen with greatest risk 
of transmission
● Use the most comprehensive pathogen-specific questionnaire
SPHL = State public health laboratory
24
Areas of State Action in Response to CIDT
Accurate case reporting
Isolate recovery
Adapting public health practice to new type of cases being reported
Assessment of resources
Prioritization for detecting disease and mitigating risk
Frequent communication with partners
25
Thank You
Alicia Cronquist, RN, MPH
Colorado Department of Public Health and Environment
Alicia.Cronquist@state.co.us
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Advancing Diagnostic Innovations and Public Health Needs
Brad Spring
Vice President, Regulatory Affairs & Compliance
BD Life Sciences (representing AdvaMedDx)
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Partnership
Advantages and Challenges
New multiplexed diagnostic tests offer 
great benefit to physicians, patients, 
and laboratories
High sensitivity and more rapid results 
as compared to conventional culture
However, these new tests may 
hinder the ability to preserve viable 
organisms needed for public health 
related activities
We support continuing partnerships to 
ensure the availability of organisms for 
surveillance and susceptibility testing
ADX: AdvaMedDx CSTE:  Council of State and Territorial Epidemiologists
APHL: Association of Public Health Laboratories 
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Concept Definition Development Qualification Launch
Product Development – An Industry Perspective
Customer requirements from “voice of customer” activities 
are gathered during concept and definition phases 
● Customer “must haves” and other requirements are documented through interviews 
with lab personnel, clinicians, administrators and other key stakeholders
● Requirements are translated into specification
● Technology solutions are chosen to meet specifications 
● Conflicting requirements can create challenges 
 e.g., cell lysis required for testing while preserving a viable organism
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Opportunities for Improvement in Product Development 
Ensure engagement with public health laboratories 
in “voice of customer” activities 
● Understand and incorporate public health needs into the 
product development process
Encourage incorporation of future public health 
needs for access to needed specimens in the event 
that a notifiable pathogen is detected
Manage conflicting product requirements
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Opportunities for Improvement in Product Development 
Future technology trends may align better 
with public health needs
● e.g., metagenomics, proteomics, and next 
generation sequencing, including whole genome 
sequencing
Work with clinical labs that develop their 
own tests 
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Opportunities to Improve Collection and Preservation of Isolates
www.aphl.org
www.cms.gov
www.fda.gov
Laboratories are required to follow manufacturers’ instructions 
according to the Clinical Laboratory Improvement Amendments (CLIA)
● AdvaMedDx members support providing APHL recommendations to clinical labs
● Information should reinforce the need to preserve isolates or clinical materials for 
submission to the appropriate public health laboratory 
 Precaution related to Public Health Reporting:  
Laboratories must follow state and/or local rules pertaining to reportable pathogens and should 
consult their local and/or state public health laboratories for isolate and/or clinical sample 
submission guidelines 
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Opportunities to Continue Collaborations
Continue to work with public health laboratories, manufacturers, and 
appropriate Federal agencies to discuss status of efforts and explore 
additional measures to aid surveillance efforts
Educational outreach with key constituency meetings
● Public health labs, microbiology groups, and industry meetings
● Manufacturers can assist by distributing education material and 
holding in-service training
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Opportunities to Better Understand the CIDT Landscape
Provide informational resources
● FDA could, for example, post a list of approved or cleared molecular diagnostics 
on the FDA website
 This will serve as a helpful resource on new molecular multi-analyte gastrointestinal 
(GI) disease agent detection panel devices that are cleared or approved with a one-
stop shop for understanding how specimens are processed  
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Next Steps: Direct-from-specimen Testing 
to Characterize Pathogens
John Besser, PhD
Deputy Chief, Enteric Diseases Laboratory Branch
Division of Foodborne, Waterborne, and Environmental Diseases 
National Center for Emerging Zoonotic and Infectious Diseases 
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Why Develop Direct-from-specimen Tests to 
Characterize Pathogens? 
Specimen compatibility with 
commercial systems 
● Even if biologically inactivated
Reduced time to actionable results
36
• More outbreaks solved more quickly
• More illnesses prevented
Case 
Confirmed
as Part of
Outbreak
Patient Eats
Contaminated
Food 
Stool
Sample
Collected
Salmonella
Identified
Shipping 
0–7 days
Public Health
Laboratory 
Receives
Sample
Serotyping 
and DNA fingerprinting 
2–10 days
Patient 
Becomes
Ill
Contact with 
health 
care system 
1–5 days
Onset of Illness
1–3 days
Diagnosis 
1–3 days
Direct-from-specimen Tests Reduce Time to Actionable Results
Opportunity to reduce reporting time
Food Vehicle 
Identified
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Stool Is a Complex Environment
Science 336:a8 1246-1247 
Lepage P, Leclerc MC, Joossens M, et al. A metagenomic insight into our gut's microbiome. Gut. 2012 Apr 23
Stool contains a variety of DNA and RNA 
● Human
● Food (consumed plant and animal material)
● Bacteria, parasites, viruses, fungi
 Average number of microbial species per person:  1,000 
 Microbial load: ~100 billion organisms per gram of stool
Some pathogens are genetically similar to 
commensal flora (i.e., other organisms 
normally found in the stool)
● e.g., Salmonella, Shiga toxin-producing E. coli
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Pathogen Marker VirulenceResistanceStrain type
STEC (STRAIN 1)
Bifidobacterium spp.
Bacteroides spp.
STEC (STRAIN 2)
Non-pathogenic E. coli
Enterobacter spp.
Fusobacteria
Direct-from-stool Pathogen Characterization
X
X
X
X
X
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Direct-from-stool Pathogen Characterization
Pathogen Marker VirulenceResistanceStrain type
STEC (STRAIN 1)
Bifidobacterium spp.
Bacteroides spp.
STEC (STRAIN 2)
Non-pathogenic E. coli
Enterobacter spp.
Fusobacteria
X
X
X
X
X
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Challenges to Direct-from-stool Pathogen Characterization
PHASING
Distinguishing 
pathogen DNA from 
closely related 
organisms’ DNA
SIGNAL-TO-NOISE
Finding pathogen 
DNA among millions 
of DNA segments in 
a sample
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Challenges to Direct-from-stool Pathogen Characterization
PHASING
Distinguishing 
pathogen DNA from 
closely related 
organisms’ DNA 
SIGNAL-TO-NOISE
Finding pathogen 
DNA among millions 
of DNA segments in 
a sample
X
Pathogen specific markerGenetic material 
shared by 
commensal flora
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Future Approaches to Pathogen Characterization 
Using Direct-from-stool Tests
Approaches
1. Pathogen-specific 
heterogeneous 
region(s)
2. Targeted wgMLST
Approaches
1. Physical mitigation
2. Hi-C 
3. Long-read sequencing
Approaches 
1. PCR-activated 
cell sorting
2. Droplet-based 
barcoding
Shotgun Metagenomics Amplicon Sequencing Single-cell Sequencing
Intermediate Near Future Long-term
wgMLST: Whole genome multilocus sequence typing
Hi-C: Variant of chromosome conformation capture technique
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Shiga toxin-
producing 
E. coli (STEC)
genome
(~5 MB)
Shiga toxin-
converting phage
A-T-C-C-G-A-A-G-T-A-G-C-A-A-G-C-T-G-GConsensus sequence
Amplicon Sequencing:  
Heterogeneous Region of Escherichia coli O157:H7 Sakai
Phage regulatory region
Shiga toxin (stx) gene
Phage genome map
Primer walking 
(overlapping amplicons) 
PCR primer of 
conserved binding sites
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A-T-C-C-G-A-A-G-T-A-G-C-A-A-G-C-T-G-G
A-T-C-C-G-A-A-G-T-A-G-C-A-A-G-C-T-G-G
A-T-C-C-G-A-A-G-T-A-G-C-A-A-G-C-T-G-G
A-T-C-C-G-A-A-G-C-A-G-C-A-A-G-C-T-G-G
A-T-C-C-G-A-A-G-T-A-G-C-A-C-G-C-T-G-G
A-T-C-C-G-A-A-G-T-A-G-C-A-C-G-C-A-G-G
A-T-C-C-G-A-A-G-T-A-G-C-A-C-G-C-A-G-G
Patient isolate 1
Patient isolate 2
Patient isolate 3
Patient isolate 4
Patient isolate 5
Patient isolate 6
Patient isolate 7
A
B
C
D
Strain 
types
Detect and 
investigate 
clusters
Amplicon Sequencing:  
Heterogeneous Region of Escherichia coli O157:H7 Sakai
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Pipeline of different processes to 
identify suitable targets 
● Identify homologous genes
● Create primers capturing variation
● Test primers for specificity
● Test subtyping resolution
Second Approach to Amplicon Sequencing:  
Targeted wgMLST of Salmonella spp.
Salmonella
genome
(~5 MB)
Test 
subtyping 
resolution
wgMLST: whole genome multilocus sequence typing
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Future Approaches to Pathogen Characterization 
Using Direct-from-stool Tests
Approaches
1. Pathogen-specific 
heterogeneous 
region(s)
2. Targeted wgMLST
Approaches
1. Physical mitigation
2. Hi-C 
3. Long-read sequencing
Approaches 
1. PCR-activated 
cell sorting
2. Droplet-based 
barcoding
Shotgun Metagenomics Amplicon Sequencing Single-cell Sequencing
Intermediate Near Future Long-term
wgMLST: Whole genome multilocus sequence typing
Hi-C: Variant of chromosome conformation capture technique
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Shotgun Metagenomics
Unbiased sequencing of 
nucleic acids recovered 
directly from an environment, 
such as a stool or sputum
Widely used for characterizing 
microbiomes
A microbiome is a community of commensal, symbiotic and 
pathogenic microorganisms that live in an area of the body 
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Detect pathogens directly 
in stool
Current capability
● Differentiate strains
Current limitations
● Insensitive
● Expensive
● Long turnaround time
● Large data computing and 
storage demands 
Shotgun Metagenomics
Partial Krona plot from patient specimen, 
Outbreak of Salmonella Heidelberg
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DNA
RNA
TNA
Many direct-from-specimen approaches are being explored 
to improve signal-to-noise, phasing, cost, and data volume!
LIBRARY
EXAMPLES
1. Nucleases (RNAse/DNAse)
2. Bind/degrade CpG
methylated DNA
3. Preferential separation
EXAMPLES
1. Differential cell lysis
2. Separation/Pulldown
3. Formaldehyde cross-
linking
EXAMPLES
1. Long read technology
2. Multiplexing and pooling
3. Bioinformatics binning 
strategies 
Strategies to Making Shotgun Metagenomics 
Practical for Public Health
SequencerSpecimen
TNA: Threose nucleic acid
SEQUENCING
POST-EXTRACTION 
AND LIBRARY CONSTRUCTION
NUCLEIC ACID
EXTRACTION
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Future Approaches to Pathogen Characterization 
Using Direct-from-stool Tests
Approaches
1. Pathogen-specific 
heterogeneous 
region(s)
2. Targeted wgMLST
Approaches
1. Physical mitigation
2. Hi-C 
3. Long-read sequencing
Approaches 
1. PCR-activated 
cell sorting
2. Droplet-based 
barcoding
Shotgun Metagenomics Amplicon Sequencing Single-cell Sequencing
Intermediate Near Future Long-term
wgMLST: Whole genome multilocus sequence typing
Hi-C: Variant of chromosome conformation capture technique
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Sorts individual cells based on selected 
characteristics, using drops with optical probe
from Dr. David Weitz, Harvard University
PCR-Activated Cell Sorting and Single Cell Sequencing
Pathogen cells
Non-pathogen 
cells
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Development of Direct-from-specimen 
Pathogen Characterization Assays
Increase compatibility between CIDTs 
and public health needs
Current technological limitations are 
likely to be overcome with research 
effort from multiple partners 
Make PulseNet more efficient and 
more effective
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To Keep Everyone Healthy, Pursue a Path that Benefits 
Patient Care and Public Health
Technology for clinical diagnoses will continue to advance
Public health continues to adapt surveillance efforts
● Modifying case definitions
● Encouraging reflex culture
● Coordinating efforts with the medical device industry 
Advancing technology for public health can 
make our lives safer
The solution is working together to develop better 
diagnostic tests to benefit patient care and public health
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